Physician profile
Suzanne Greb
NPI 1780609701
$3,667.69
in general payments reported to CMS, 2019-2025
27 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $263 · 2021: $16.43 · 2022: $29.64 · 2023: $521 · 2024: $843 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.02 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.89 | 2020-2025 | |
| Novo Nordisk INC | $506.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $461.31 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $448.82 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.25 | 2019-2025 | Tradjenta, Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $232.66 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $202.25 | 2019-2025 | |
| Exact Sciences Corporation | $171.68 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $118.08 | 2019-2025 | Evenity, Prolia, Repatha |
| Averitas Pharma INC. | $113.77 | 2023 | Qutenza |
| Merck Sharp & Dohme LLC | $89.58 | 2019-2025 | Gardasil 9, Vaxelis, Proquad |
| Astellas Pharma US INC | $88.20 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $52.05 | 2019-2020 | |
| Dexcom, INC. | $51.99 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $42.53 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.34 | 2024-2025 | Voquezna |
| Allergan, INC. | $34.28 | 2019 | |
| Sumitomo Pharma America, INC. | $34.00 | 2023-2025 | Gemtesa |
| Sanofi Pasteur INC. | $32.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.25 | 2019 | |
| Shire North American Group INC | $28.45 | 2019 | |
| Alnylam Pharmaceuticals INC. | $27.81 | 2025 | Onpattro |
| Shield Therapeutics INC | $25.30 | 2023 | Accrufer |
| Ibsa Pharma INC. | $22.61 | 2025 | Flector, Licart, Tirosint |
| E.R. Squibb & Sons, L.L.C. | $20.45 | 2019 | |
| Philips North America LLC | $18.12 | 2024 | (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Greb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.